source
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugOn a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
- Recon: Merck KGaA to exit CDMO business; Karyopharm to sell itself in bankruptcyWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 17d ago↗ source
- FDA sets May 1 decision date for uniQure's Huntington's disease gene therapy after year-long regulatory saga